The European Medicines Agency (EMA) has updated its general guidelines on the development of medicinal products for Major Depressive Disorder (MDD) to include a section on...
In a new policy briefing for the European Medicines Agency (EMA), Psychedelic Access and Research European Alliance (PAREA) has called for an advisory body on psychedelics...
In the latest development for psychedelics in the UK, the Home Affairs Committee Drug Report has seen MPs call for a review of drug scheduling in...
With a rise in clinical trials investigating psychedelics for a number of mental health conditions, the UK’s Parliamentary Office of Science and Technology (POST) has issued...
The Psychedelic Access and Research Alliance (PAREA) has released a position statement calling on the EU to harness psychedelics in a bid to create innovation in...
In light of clinical research showing MDMA-assisted therapy as a potential treatment for PTSD, at PSYCH Symposium in the British Museum on 6 July a conversation...
PSYCH Symposium returned at the British Museum on 6 July to explore how psychedelic medicines can innovate healthcare – from mental health to eating disorders and...
Timmy Davis of the Conservative Drug Policy Reform Group (CDPRG) tells Psychedelic Health about the organisation’s campaign to reschedule psilocybin in a bid to increase psychedelic...
In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on...
MP Crispin Blunt raised a point of order in the House of Commons after the UK’s Drugs Minister failed to show up for a debate on...
